Citius Pharmaceuticals, Inc. (CTXR)
$
0.84
Key metrics
Financial statements
Free cash flow per share
-1.6206
Market cap
9.3 Million
Price to sales ratio
2.3660
Debt to equity
0.0229
Current ratio
0.9931
Income quality
0.9245
Average inventory
22.5 Million
ROE
-0.5254
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company founded in 2007 and headquartered in Cranford, New Jersey, engages in the development and commercialization of critical care products with a focus on anti-infective solutions in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Currently, the company is advancing five proprietary products: Mino-Lok, an antibiotic lock solution aimed at treating catheter-related bloodstream infections by salvaging infected catheters; Mino-Wrap, a liquifying gel-based wrap designed to reduce tissue expander infections post-breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation targeting anti-inflammatory and anesthetic relief for hemorrhoid sufferers; NoveCite, a mesenchymal stem cell therapy intended for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein developed for patients with persistent or recurrent cutaneous T-cell lymphoma. The weighted average number of shares outstanding is 11,065,225.00 highlighting the company's shareholder base and its commitment to transparency. The company incurred an interest expense of $267,782.00 reflecting its debt servicing obligations. Moreover, the net income ratio is 0.00 indicating the company's profitability margin. Additionally, the net total of other income and expenses is -$157,701.00 reflecting non-core financial activities, while the gross profit ratio is 0.00 demonstrating the efficiency of the company’s production and sales operations. In terms of market positioning, the stock is affordable at $1.19 making it suitable for budget-conscious investors. However, it has a low average trading volume of 858,247.00 indicating lower market activity which might appeal to specific investor profiles. With a market capitalization of $9,375,406.00 the company is classified as a small-cap player, which often attracts investors interested in growth opportunities. Citius Pharmaceuticals, Inc. is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and fostering growth in critical therapeutic areas that address pressing healthcare needs.
Is Citius Pharmaceuticals, Inc. (CTXR) a good investment?
Investing in Citius Pharmaceuticals, Inc. (CTXR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Citius Pharmaceuticals, Inc. (CTXR)'s stock forecast?
Analysts predict Citius Pharmaceuticals, Inc. stock to fluctuate between $0.63 (low) and $2.48 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Citius Pharmaceuticals, Inc.'s market capitalization?
As of 2026-03-10, Citius Pharmaceuticals, Inc.'s market cap is $9,375,406, based on 11,174,500 outstanding shares.
How does Citius Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Citius Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Citius Pharmaceuticals, Inc. (CTXR) stock?
To buy Citius Pharmaceuticals, Inc. (CTXR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CTXR. Place an order (Market, Limit, etc.).
What is the best time to invest in Citius Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Citius Pharmaceuticals, Inc. stock ever split?
Citius Pharmaceuticals, Inc.'s last stock split was 1:15 on 2017-06-09.
How did Citius Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$3.38 | Growth: -43.38%.
Where can I find Citius Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.citiuspharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Citius Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Citius Pharmaceuticals, Inc. stock?
All-time high: $58.75 (2021-08-30) | All-time low: $0.63 (2025-12-24).
What are the key trends affecting Citius Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data of University of Pittsburgh-led trial to be presented at an upcoming international cancer conference later this year CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators.
prnewswire.com
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update.
prnewswire.com
Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J. , Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year ended September 30, 2025.
prnewswire.com
Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE LYMPHIR international availability extends to 19 markets outside the U.S. CRANFORD, N.J. , Dec. 4, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has entered into an exclusive distribution agreement with Er-Kim İlaç Sanayi ve Ticaret A.
prnewswire.com
Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch CRANFORD, N.J. , Nov. 21, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced a deeper collaboration with Verix, a leader in AI-powered commercial optimization technology for the life sciences sector.
prnewswire.com
LD Micro Main Event XIX, October 19-21, 2025 2025 Maxim Growth Summit, October 22-23, 2025 The Think Equity Conference, October 30, 2025 CRANFORD, N.J. , Oct. 17, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and Citius Oncology, Inc. (Nasdaq: CTOR) today announced that management will be participating in three investor conferences in October 2025.
prnewswire.com
EVERSANA to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy CRANFORD, N.J. , Oct. 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it has finalized an exclusive agreement with EVERSANA® , a leading provider of global commercialization services, to support the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl), Citius Oncology's FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy.
prnewswire.com
CRANFORD, N.J. , Sept. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced the closing of its previously announced registered direct offering and concurrent private placement of an aggregate of 5,142,858 shares of common stock and unregistered warrants to purchase up to an aggregate of 5,142,858 shares of common stock.
prnewswire.com
CRANFORD, N.J. , Sept. 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,142,858 shares of common stock in a registered direct offering.
prnewswire.com
$12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction CRANFORD, N.J. , Aug. 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported financial results for its fiscal third quarter ended June 30, 2025, and provided a business update.
See all news
